These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7853924)

  • 41. Biotech patents-business as usual?
    Lawrence S
    Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
    [No Abstract]   [Full Text] [Related]  

  • 42. Effect of generic drug competition on the price of prescription drugs in Ontario.
    Lexchin J
    CMAJ; 1993 Jan; 148(1):35-8. PubMed ID: 8439888
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS
    Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
    [No Abstract]   [Full Text] [Related]  

  • 44. How Genentech Novartis stifled a promising drug: biotech firm tried to pursue a peanut allergy inject, but contract got in way; Zach avoids a "kiss of death".
    Hamilton DP
    Wall St J (East Ed); 2005 Apr; ():A1, A10. PubMed ID: 15926244
    [No Abstract]   [Full Text] [Related]  

  • 45. Industrial policy and its relevance to vaccines manufacturers.
    Donnelly MC
    Biologicals; 1997 Jun; 25(2):125-9. PubMed ID: 9236038
    [No Abstract]   [Full Text] [Related]  

  • 46. Prescription for the Orphan Drug Act: the impact of the FDA's 1992 regulations and the latest congressional proposals for reform.
    Clissold DB
    Food Drug Law J; 1995; 50(1):125-47. PubMed ID: 10342989
    [No Abstract]   [Full Text] [Related]  

  • 47. The pharmaceutical industry--to whom is it accountable?
    Rightor N
    N Engl J Med; 2000 Nov; 343(19):1416; discussion 1417. PubMed ID: 11183882
    [No Abstract]   [Full Text] [Related]  

  • 48. The North American Free Trade Agreement's effect on pharmaceutical patents: a bitter pill to swallow or a therapeutic solution?
    Silbermann JM
    J Contemp Health Law Policy; 1996; 12(2):607-36. PubMed ID: 8666736
    [No Abstract]   [Full Text] [Related]  

  • 49. European Union joins fight over drug patents.
    Watson R
    BMJ; 2001 Jul; 323(7303):12. PubMed ID: 11440933
    [No Abstract]   [Full Text] [Related]  

  • 50. Realizing two-tiered innovation policy through drug regulation.
    Ridgway WE
    Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
    [No Abstract]   [Full Text] [Related]  

  • 51. Price regulation and generic competition in the pharmaceutical market.
    Dalen DM; Strøm S; Haabeth T
    Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV
    Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
    [No Abstract]   [Full Text] [Related]  

  • 53. [Two years with EMEA: towards a unified drug registration within the EEC].
    Lennholm B
    Lakartidningen; 1997 Jan; 94(1-2):8-12. PubMed ID: 9053613
    [No Abstract]   [Full Text] [Related]  

  • 54. Drug promotion.
    Mossinghoff GJ
    N Engl J Med; 1995 Apr; 332(15):1032; author reply 1033. PubMed ID: 7885415
    [No Abstract]   [Full Text] [Related]  

  • 55. 2 billion euro IMI launched with European pharma.
    Hodgson J
    Nat Biotechnol; 2008 Jul; 26(7):717-8. PubMed ID: 18612274
    [No Abstract]   [Full Text] [Related]  

  • 56. Cost-effectiveness data on biologics needed.
    Sheridan C; Katsnelson A
    Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069
    [No Abstract]   [Full Text] [Related]  

  • 57. Path to approval proves rocky for copycat biodrugs.
    Wadman M
    Nature; 2005 Nov; 438(7065):154-5. PubMed ID: 16281004
    [No Abstract]   [Full Text] [Related]  

  • 58. [The EEC creates a European Medical Product Agency].
    Johnson K
    Lakartidningen; 1993 Oct; 90(40):3395. PubMed ID: 8231477
    [No Abstract]   [Full Text] [Related]  

  • 59. [An interview with Dr. D. Poggiolini, director of the Pharmaceutical Service of the Health Ministry and the Drug Committee of the EEC. Interview by Giuseppe Lojacono].
    Poggiolini D
    Epidemiol Prev; 1988 Dec; 10(37):9. PubMed ID: 2978859
    [No Abstract]   [Full Text] [Related]  

  • 60. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA
    Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.